GW Pharma (GWPH) M&A $7.75M Settlement

GW Pharma (GWPH) agreed to pay $7.75 million to Investors to avoid further litigation.

Investors who purchased, sold, or held $GWPH at any time during the period from and including March 10, 2021, through and including May 5, 2021, may be affected by the Settlement of this Litigation.

• On February 3, 2021, GW entered into a merger agreement where GW ordinary shareholders would receive $16.66 in cash and $Jazz shares based on an exchange ratio calculated from Jazz's share price, while GW American Depositary Shares holders would receive approximately $200 per share in cash and $20 in Jazz stock;

• However, shareholder complaint alleged that $GWPH disseminated a materially false and misleading Definitive Proxy Statement to persuade GW shareholders to vote in favor of the Merger, containing inaccuracies regarding GW's financial projections, stock value, and the fairness of the Merger Consideration.